JP2009502208A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502208A5
JP2009502208A5 JP2008525274A JP2008525274A JP2009502208A5 JP 2009502208 A5 JP2009502208 A5 JP 2009502208A5 JP 2008525274 A JP2008525274 A JP 2008525274A JP 2008525274 A JP2008525274 A JP 2008525274A JP 2009502208 A5 JP2009502208 A5 JP 2009502208A5
Authority
JP
Japan
Prior art keywords
peptides
fragments
derivatives
peptide
homologues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008525274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/030686 external-priority patent/WO2007019426A2/en
Publication of JP2009502208A publication Critical patent/JP2009502208A/ja
Publication of JP2009502208A5 publication Critical patent/JP2009502208A5/ja
Pending legal-status Critical Current

Links

JP2008525274A 2005-08-05 2006-08-07 エネルギーホメオスタシスに関係する新規ペプチド Pending JP2009502208A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70594005P 2005-08-05 2005-08-05
PCT/US2006/030686 WO2007019426A2 (en) 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis

Publications (2)

Publication Number Publication Date
JP2009502208A JP2009502208A (ja) 2009-01-29
JP2009502208A5 true JP2009502208A5 (enExample) 2010-07-15

Family

ID=37727967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525274A Pending JP2009502208A (ja) 2005-08-05 2006-08-07 エネルギーホメオスタシスに関係する新規ペプチド

Country Status (10)

Country Link
US (4) US20090253619A1 (enExample)
EP (1) EP1928487A4 (enExample)
JP (1) JP2009502208A (enExample)
KR (1) KR101004662B1 (enExample)
CN (1) CN101505786A (enExample)
AU (2) AU2006278406B2 (enExample)
CA (1) CA2618047C (enExample)
IL (2) IL189065A (enExample)
RU (2) RU2409590C2 (enExample)
WO (1) WO2007019426A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US11246912B2 (en) * 2017-08-30 2022-02-15 Hadasit Medical Research Services & Development Ltd. Methods for treating and diagnosing metastatic liver cancer
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
WO2024263938A2 (en) * 2023-06-23 2024-12-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Using enho gene therapy to treat cardiometabolic disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078345C1 (ru) * 1992-04-03 1997-04-27 Аникеева Светлана Петровна Способ получения сывороточного белкового препарата, влияющего на активность окислительно-энергетического обмена
US20030096951A1 (en) * 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Similar Documents

Publication Publication Date Title
JP2010534684A5 (enExample)
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
HRP20201353T1 (hr) Agonisti glukagonskog receptora
PH12012502121A1 (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
NZ737050A (en) Glucagon and glp-1 co-agonist compounds
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
PE20121393A1 (es) Analogo peptidico de oxintomodulina
MX2012013375A (es) Peptido c pegilado.
WO2007121411A3 (en) Glucagon-like peptide 1(glp-1) pharmaceutical formulations
GEP20176629B (en) Glucagon/glp-1 receptor co-agonists
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
MX2010004297A (es) Antagonistas de glucagon.
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
NZ608502A (en) Polypeptides that bind to human complement component c5
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
NZ612161A (en) Radiolabled her2 binding peptides
WO2011156453A3 (en) Therapeutic peptides
MX2008009493A (es) Peptido novedoso y uso del mismo.
JP2014532722A5 (enExample)
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy